B+
Bull case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
ABEO
Abeona TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Recent coverage is sparse and centered on Q2 launch progress. The operating tone is mixed: sequential ZEVASKYN revenue growth, additional treatments, QTC expansion, and NTAP support are constructive, while manufacturing exceptions and uncertain patient cadence constrain visibility. ABO-701 supplies a distinct long-horizon program, but it remains pre-IND without a disclosed timetable and therefore adds optionality rather than near-term conviction. KRYS and private Chiesi are treatment-landscape comparators, but product and corporate differences prevent clean valuation read-throughs. No sufficient social, options, short-interest, employee, post-release price-reaction, or analyst-revision data were supplied; zero values in those fields denote unavailable evidence rather than neutral measurements. The deterministic prior is neutral, supporting a cautious monitoring stance.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-01eventCMS NTAP becomes effectiveHigh impact
ZEVASKYN's CMS New Technology Add-On Payment status becomes effective October 1, 2026, providing eligible hospitals supplemental reimbursement for Medicare patients and potentially easing adoption and access. Medicare patients represent approximately 10% of the indicated RDEB population. [#SEC-8K-2026-08-13]
2026-12-11catalystManufacturing reliability and revenue recognitionHigh impact
Revenue was not recognized for two treated patients because of low manufacturing yield or failure to meet lot-release specifications. Evidence that these are isolated events would reduce launch risk; recurrence would pressure revenue, margins, and confidence in scaling. [#SEC-8K-2026-08-13]
2027-06-30catalystZEVASKYN treatment-center throughput scalesHigh impact
Abeona reported seven activated qualified treatment centers, five patients treated in Q2, three more in Q3 through August 13, and 12 treatments since launch. Sustained growth in completed, revenue-recognized treatments would validate commercial execution, but center onboarding and patient timing remain variable. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology